At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 6,998 enrolled
Drug / intervention
FTY720drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
In Brief
A Phase 4 clinical trial evaluating FTY720 for Multiple Sclerosis. Completed, enrolled 6,998 participants across 258 sites.
Detailed Summary
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartApr 2012
Primary CompletionDec 2016
TodayJul 2026
First PostedApr 25, 2012
Enrollment StartApr 29, 2012
Primary CompletionDec 12, 2016
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 14.2 years ago
Interventions
FTY720drug